| pubmed-article:3381606 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C0035168 | lld:lifeskim |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C0004093 | lld:lifeskim |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C0033978 | lld:lifeskim |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:3381606 | lifeskim:mentions | umls-concept:C0053083 | lld:lifeskim |
| pubmed-article:3381606 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3381606 | pubmed:dateCreated | 1988-7-19 | lld:pubmed |
| pubmed-article:3381606 | pubmed:abstractText | In a series of 130 patients with asthenic conditions related to borderline forms of neuro-mental disturbances the authors compared clinico-pharmacological action of the actoprotector bemitil with that of nootropic drugs (piracetam and piridotol). The treatment with bemitil was either continuous or intermittent, being conducted according to the scheme elaborated in the course of the study. Bemitil proved to be more effective than piracetam and piriditol in relation to its influence on the manifestations of the asthenic symptom complex in general. Its application was characterized by a faster onset of the therapeutic effect and a peculiar mild psychostimulating action, primarily manifested in the impact on obligate manifestations of the asthenic disorders. The degree of the psychotropic action of the drug was found to be subject to changes depending on the scheme of its use. | lld:pubmed |
| pubmed-article:3381606 | pubmed:language | rus | lld:pubmed |
| pubmed-article:3381606 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3381606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3381606 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3381606 | pubmed:issn | 0044-4588 | lld:pubmed |
| pubmed-article:3381606 | pubmed:author | pubmed-author:Aleksandrovsk... | lld:pubmed |
| pubmed-article:3381606 | pubmed:author | pubmed-author:SerebriakovaT... | lld:pubmed |
| pubmed-article:3381606 | pubmed:author | pubmed-author:Bo?koS SSS | lld:pubmed |
| pubmed-article:3381606 | pubmed:author | pubmed-author:BobkovIu GIuG | lld:pubmed |
| pubmed-article:3381606 | pubmed:author | pubmed-author:NeznamovG GGG | lld:pubmed |
| pubmed-article:3381606 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3381606 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:3381606 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3381606 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3381606 | pubmed:pagination | 109-15 | lld:pubmed |
| pubmed-article:3381606 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:meshHeading | pubmed-meshheading:3381606-... | lld:pubmed |
| pubmed-article:3381606 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3381606 | pubmed:articleTitle | [Use of the new psychotropic preparation bemitil in treating asthenic disorders (clinico-pharmacological research)]. | lld:pubmed |
| pubmed-article:3381606 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3381606 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:3381606 | pubmed:publicationType | English Abstract | lld:pubmed |
